ArticleHepatology (Baltimore, Md.)2020
Bespoken Nanoceria: An Effective Treatment in Experimental Hepatocellular Carcinoma.
Open access · hybridAbstract read
In one paragraph
Article in Hepatology (Baltimore, Md.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.
- Effectiveness of Cerium Oxide Nanoparticles in Non-Alcoholic Fatty Liver Disease Evolution Using In Vivo and In Vitro Studies: A Systematic Review.International journal of molecular sciences · 2023Pooled it
- Biological Applications of Functionalized Cerium Oxide Nanoparticles.International journal of medical sciences · 2026Review
- The Dual-Faceted Role of Metal-Based Nanomaterials in Hepatic Fibrosis Therapy.International journal of nanomedicine · 2026Review
- Insights into the causal role of diesel exhaust particles in ventricular arrhythmogenesis: protective effects of antioxidant cerium oxide nanoparticles.Particle and fibre toxicology · 2025Article
- Response of Ocular Bacteria Exposure to Cerium Oxide Nanoparticles in Eye Drop Formulation.Current microbiology · 2025Article
- Nanoceria as Next-Generation Immunotherapeutics: Applications in Chronic Inflammation, Cancer, and Tissue Repair.Journal of nanotheranostics · 2025Article
- Review
- Article
- Protective effects of bone marrow mesenchymal stem cell-derived exosomes loaded cerium dioxide nanoparticle against deoxynivalenol-induced liver damage.Journal of nanobiotechnology · 2025Article
- Harnessing nanoparticles for reshaping tumor immune microenvironment of hepatocellular carcinoma.Discover oncology · 2025Review
- Therapeutic Potential of PDA@CeO2 in Suppressing Hepatic Stellate Cell Activation and Preventing Liver Fibrosis.International journal of nanomedicine · 2025Article
- Effect of cerium oxide on iron metabolism in mice.Journal of clinical biochemistry and nutrition · 2024Article
- Nanomaterials modulate tumor-associated macrophages for the treatment of digestive system tumors.Bioactive materials · 2024Review
- Cerium oxide nanoparticles: Chemical properties, biological effects and potential therapeutic opportunities (Review).Biomedical reports · 2024Review
- MRPL48 is a novel prognostic and predictive biomarker of hepatocellular carcinoma.European journal of medical research · 2023Article
- Cerium oxide nanoparticles-carrying human umbilical cord mesenchymal stem cells counteract oxidative damage and facilitate tendon regeneration.Journal of nanobiotechnology · 2023Article
- From liver fibrosis to hepatocarcinogenesis: Role of excessive liver HBioactive materials · 2023Article
- Exploring the Long-Term Tissue Accumulation and Excretion of 3 nm Cerium Oxide Nanoparticles after Single Dose Administration.Antioxidants (Basel, Switzerland) · 2023Article
- Targeting tumor-associated macrophages in hepatocellular carcinoma: biology, strategy, and immunotherapy.Cell death discovery · 2023Review
- Nanoceria: an innovative strategy for cancer treatment.Cellular and molecular life sciences : CMLS · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 5 institutions in 3 countries.
Guillermo Fernández-VaroService of Biochemistry and Molecular Genetics, Hospital Clinic Universitari, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.ORCID 0000-0002-7776-3300
Meritxell PerramónService of Biochemistry and Molecular Genetics, Hospital Clinic Universitari, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.ORCID 0000-0002-1944-8337
Silvia CarvajalService of Biochemistry and Molecular Genetics, Hospital Clinic Universitari, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Denise OróService of Biochemistry and Molecular Genetics, Hospital Clinic Universitari, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Eudald CasalsSchool of Biotechnology and Health Sciences, Wuyi University, Jiangmen, China.
Loreto BoixBarcelona-Clinic Liver Cancer Group, Liver Unit, Hospital Clinic de Barcelona, CIBERehd, IDIBAPS, University of Barcelona, Barcelona, Spain.
Laura OllerService of Biochemistry and Molecular Genetics, Hospital Clinic Universitari, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Laura Macías-MuñozService of Biochemistry and Molecular Genetics, Hospital Clinic Universitari, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Santi MarfàService of Biochemistry and Molecular Genetics, Hospital Clinic Universitari, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Gregori CasalsService of Biochemistry and Molecular Genetics, Hospital Clinic Universitari, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Manuel Morales-RuizService of Biochemistry and Molecular Genetics, Hospital Clinic Universitari, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Pedro CasadoCentre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.ORCID 0000-0002-4207-9349
Pedro R CutillasCentre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.
Jordi BruixBarcelona-Clinic Liver Cancer Group, Liver Unit, Hospital Clinic de Barcelona, CIBERehd, IDIBAPS, University of Barcelona, Barcelona, Spain.
Miquel NavasaLiver Surgery and Transplant Unit, Digestive and Metabolic Diseases Institute, Hospital Clínic of Barcelona, CIBERehd, IDIBAPS, University of Barcelona, Barcelona, Spain.
Josep FusterLiver Surgery and Transplant Unit, Digestive and Metabolic Diseases Institute, Hospital Clínic of Barcelona, CIBERehd, IDIBAPS, University of Barcelona, Barcelona, Spain.
Juan Carlos Garcia-ValdecasasLiver Surgery and Transplant Unit, Digestive and Metabolic Diseases Institute, Hospital Clínic of Barcelona, CIBERehd, IDIBAPS, University of Barcelona, Barcelona, Spain.
Mihai C PavelLiver Surgery and Transplant Unit, Digestive and Metabolic Diseases Institute, Hospital Clínic of Barcelona, CIBERehd, IDIBAPS, University of Barcelona, Barcelona, Spain.
Víctor PuntesInstitut Català de Recerca i Estudis Avançats (ICREA), Barcelona, Spain.
Wladimiro JiménezService of Biochemistry and Molecular Genetics, Hospital Clinic Universitari, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.ORCID 0000-0002-9376-0214
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas · ESHospital Clínic de Barcelona · ESQueen Mary University of London · GBInstitució Catalana de Recerca i Estudis Avançats · ESWuyi University · CN
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsDespite the availability of new-generation drugs, hepatocellular carcinoma (HCC) is still the third most frequent cause of cancer-related deaths worldwide. Cerium oxide nanoparticles (CeO APPROACH AND
resultsHCC was induced in 110 Wistar rats by intraperitoneal administration of diethylnitrosamine for 16 weeks. Animals were treated with vehicle or CeO
conclusionsThese data indicate that CeO
Indexed as
alpha-FetoproteinsAnimalsApoptosisCarcinoma, HepatocellularCeriumHumansLipid MetabolismLiverLiver Neoplasms, ExperimentalMaleNanoparticlesRatsRats, WistarSignal Transductionalpha-Fetoproteinsceric oxideCerium
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.